Neuroendocrine Cancer: Radiotherapy
The question
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the National Institute for Health and Social Care on providing guidance on the adoption of selective internal radiation therapy for patients with neuroendocrine tumours .
Answered by Karin Smyth
The Department has had no such discussions. In May 2024, the National Institute for Health and Care Excellence (NICE) published interventional procedures guidance that recommends that selective internal radiation therapy can be used as an option for neuroendocrine tumours that have metastasised to the liver, with standard arrangements in place for clinical governance, consent, and audit. The NICE’s interventional procedures make recommendations based on an assessment of safety and efficacy, but do not consider whether the procedure represents a clinically and cost-effective use of National Health Service resources. NHS commissioners are responsible for decisions on whether procedures recommended in the NICE’s interventional procedures guidance should be routinely offered to NHS patients.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →